Project Grant R01HL172214
Award Date 8/10/26
Completion Date 4/30/31
Dollars Obligated $454K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $1.669 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for data-consistent motion-correction reconstruction of PET/MR imaging targeting coronary atherosclerotic plaque activity. The research addresses motion artifacts that degrade spatial resolution and quantitative accuracy in coronary PET imaging, particularly for low-count tracers such as 68GA-DOTATATE....
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $570,666 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a streamlined base editor reengineering platform that enhances gene editing specificity and selectivity for therapeutic applications. The recipient will establish an engineering platform to accelerate base editor development by integrating a naturally occurring...
- The National Heart, Lung, and Blood Institute awarded New York Institute of Technology $573,750 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lysosomal membrane permeabilization in doxorubicin-induced cardiotoxicity. The research redefines understanding of how doxorubicin, a powerful cancer therapeutic, causes heart failure by focusing on lysosomal dysfunction in cardiomyocytes. Rather than emphasizing lysosomal protease release...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $462,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comparative analysis of thrombogenic risk across menopausal stages in women with HIV. The research examines sex-based differences in cardiovascular disease risk among women with HIV, focusing on how immune activation, platelet reactivity, and age-related changes in sex hormones interact to elevate...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $850,669 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate place-based drivers of health in sickle cell disease pathogenesis. The project will identify and quantify mechanisms linking neighborhood and personal exposures—including crime-related stressors, unhealthy food access, temperature, airborne particulates, and housing conditions—to clinical...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $873,801 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epithelial reprogramming mechanisms that distinguish normal regenerative repair from pathologic fibrotic remodeling in chronic lung diseases, particularly idiopathic pulmonary fibrosis. The research examines how airway and alveolar epithelial stem and progenitor cells progress through intermediate...